<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724798</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2020-021</org_study_id>
    <nct_id>NCT04724798</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Tigecycline in Patients Treated With ECMO</brief_title>
  <official_title>Population Pharmacokinetics of Tigecycline in Patients Treated With ECMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tigecycline is a commonly used antibiotic in critically ill patients. The pharmacokinetics&#xD;
      (PK) of tigecycline in intensive care unit (ICU) patients can be affected by severe&#xD;
      pathophysiological changes so that standard dosing might not be adequate. At present, a&#xD;
      number of studies have reported that ECMO will affect the PK of anti-infective drugs and lead&#xD;
      to treatment failure. The purpose of this study was to describe the population PK of&#xD;
      tigecycline in patients treated with ECMO and to evaluate the relationship between individual&#xD;
      PK parameters and patient covariates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum drug concentration of tigecycline</measure>
    <time_frame>predose, 2 min, 5 min, 15 min, 30 min, 1 hour, 3 hours, 6 hours, 12 hours, and 24 hours post-dose</time_frame>
    <description>Serum drug concentration at different time points in each adult ICU patient treated with ECMO</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Tigecycline</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        critically ill hospitalized males or nonpregnant females aged ≥18 years with severe&#xD;
        infections which the treating clinician was treating with tigecycline.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  critically ill hospitalized males or nonpregnant females aged ≥18 years with severe&#xD;
             infections which the treating clinician was treating with tigecycline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People who had taken tigecycline in the past week&#xD;
&#xD;
          -  People who were pregnant&#xD;
&#xD;
          -  People who had coagulation dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuan Zhang, doctor</last_name>
    <phone>+8615626182275</phone>
    <email>m15626182275@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenhua Zeng, doctor</last_name>
    <phone>+8615692428912</phone>
    <email>zhenhuazeng.2008@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southern medical university Nanfang hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Zhang, doctor</last_name>
      <phone>+8615626182275</phone>
      <email>m15626182275@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Zhenhua Zen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

